This contrasts with loss of AQP4 expression in NMO, a demyelinating disease in which AQP4 autoantibodies are not only a highly specific biomarker for the disease, but are involved in disease pathology as well [76], despite some controversy for the latter [77]. Here, AQP4 is linked to demyelinating disease.